Novo Nordisk A/S $NVO Shares Purchased by Generate Investment Management Ltd

Key Points

• Generate Investment Management Ltd boosted its stake in Novo Nordisk by 43.2%, adding 69,423 shares to hold 229,962 shares worth about $12.76 million at quarter-end.
• The FDA approval of the Wegovy oral pill is a major commercial catalyst that could expand Novo’s market, but the company faces margin pressure from price cuts (notably in China) and intense competition from Eli Lilly.
• Analysts’ consensus is a Hold with an average target of $53.33; Novo recently beat quarterly EPS ($1.02 vs. $0.77) though revenue slightly missed estimates, and its market cap is roughly $228.6 billion.

Generate Investment Management Ltd increased its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 43.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 229,962 shares of the company's stock after acquiring an additional 69,423 shares during the quarter. Generate Investment Management Ltd's holdings in Novo Nordisk A/S were worth $12,761,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in NVO. NewSquare Capital LLC increased its stake in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company's stock valued at $31,000 after acquiring an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter worth about $37,000. State of Wyoming purchased a new stake in Novo Nordisk A/S during the first quarter worth approximately $38,000. Maseco LLP acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $39,000. Finally, Copeland Capital Management LLC increased its holdings in Novo Nordisk A/S by 47.3% in the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company's stock valued at $40,000 after purchasing an additional 186 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. BMO Capital Markets reaffirmed a "market perform" rating on shares of Novo Nordisk A/S in a research report on Tuesday, December 23rd. HSBC restated a "hold" rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Rothschild Redb raised shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 16th. The Goldman Sachs Group cut their target price on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a "buy" rating on the stock in a report on Friday, November 28th. Finally, Morgan Stanley restated an "underweight" rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $53.33.

Novo Nordisk A/S Trading Down 0.5%

Shares of Novo Nordisk A/S stock opened at $51.19 on Wednesday. The stock has a market capitalization of $228.55 billion, a P/E ratio of 14.88 and a beta of 0.67. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a 50-day simple moving average of $49.19 and a 200 day simple moving average of $56.21.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The business had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves Wegovy oral pill — a major commercial milestone that opens a new, non‑injectable patient segment and supports a planned U.S. launch in early 2026. This is the key bullish catalyst many investors celebrated. Read More.
• Positive Sentiment: First‑mover and efficacy edge vs. Lilly’s oral candidate — analysts note Novo may have a head start on oral GLP‑1 market share and trial data show strong weight‑loss results for oral Wegovy, which could help retention vs. competitors. Read More.
• Neutral Sentiment: Macro/ETF flow tailwinds — FDA nod to an oral GLP‑1 is expected to lift healthcare and obesity‑focused ETFs, bringing incremental investor demand even as company fundamentals are reassessed. Read More.
• Neutral Sentiment: Short‑term market reaction volatility — coverage notes big share swings after the approval (both big pops and pullbacks) as investors reprice growth expectations for 2026. Read More.
• Negative Sentiment: Price cuts in China and margin pressure — Novo has cut Wegovy prices in some Chinese provinces and trimmed prices ahead of generic threats, which alongside broader pricing moves could compress margins. Read More. Read More.
• Negative Sentiment: Margins and investor impatience — commentary warns oral product economics and broader price competition could erode profitability; some analysts flag the risk that oral Wegovy and aggressive pricing will pressure margins and investor patience. Read More.
• Negative Sentiment: Intense competition from Eli Lilly — Lilly’s tirzepatide franchise and its oral candidate keep competitive pressure high; market share and pricing battles remain key downside risks. Read More. Read More.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company's core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.